Willem de Haan, MD, PhD, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, explores the utility of electroencephalography (EEG) as a biomarker in Alzheimer’s disease (AD) clinical trials. In clinical trials for potential AD drugs, the common desired outcome is an improvement in cognition. However, to comprehend the drug mechanisms driving this cognitive improvement, it’s essential to understand the changes in neuronal behavior that improve brain function, and this is where EEG plays a pivotal role. EEGs offer a direct assessment of neuronal and synaptic function, are readily available, user-friendly, and capable of detecting activity changes quickly, making them valuable for use in relatively short trials. This interview took place at the Clinical Trials on Alzheimer’s Disease (CTAD) congress 2023 in Boston.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
